Powell Max Limited Class A Ordinary Shares
PMAX News Today: Stay Updated with the Latest Powell Max Limited Class A Ordinary Shares News in Real Time
Find PMAX news now at Meyka AI. Stay informed with the latest Powell Max Limited Class A Ordinary Shares stocks updates, including price news, market analysis, and expert insights.
Xiaomi Stock Climbs Ahead of May 26 Earnings, Trading at €3.37
3CP.F stock trades at €3.37 on XETRA ahead of May 26 earnings announcement. Meyka AI rates the stock B+ with neutral recommendation.
AsiaPhos Limited Tumbles 22% as Phosphate Chemicals Demand Weakens
5WV.SI stock crashes 22% to S$0.007 on weak demand. AsiaPhos Limited faces strong sell rating amid negative cash flow and losses.
NVDA Stock Today May 21: Earnings Beat Sparks AI Factory Boom
Nvidia beats Q1 earnings with $81.62B revenue, $1.87 EPS. Stock slides despite strong results as AI factory buildout accelerates.
Spearmint Resources Inc. (SPMT.CN) Plunges 33% as Lithium Exploration Stalls
SPMT.CN stock crashes 33% to C$0.005 amid exploration delays. Meyka AI rates the stock C- with a Strong Sell recommendation.
New Age Exploration Limited Crashes 50% as NAE.AX Hits Record Low
NAE.AX stock plummets 50% to A$0.001 on May 21, 2026. Exploration company faces severe headwinds with negative cash flow and weak fundamentals.
FECHF Stock Climbs to $3.49 as China Fund Eyes Growth Opportunities
FECHF stock trades at $3.49 with $1.6B market cap. Fidelity China Special Situations PLC focuses on growth stocks across Chinese markets.
Sharp Chucks & Machines Ltd. Tumbles 20% as SCML.NS Hits 52-Week Low
SCML.NS stock crashes 20% to ₹113.2, hitting 52-week lows. Industrial machinery maker faces technical oversold conditions and weak momentum.
Trump Tax Deal May 21: US President Halts IRS Audits on Steuer
Trump’s tax deal halts IRS audits on president and family. Justice Department stops federal tax investigations into Trump’s finances and businesses.
PTCT Maintained at Buy by BofA Securities, May 2026
Bank of America Securities maintains Buy rating on PTC Therapeutics (PTCT), citing $2bn+ Sephience sales opportunity.